Sirius Therapeutics
Recent Finacing
Series B II
Recent Raise
$50M
Sirius Therapeutics develops siRNA therapeutics and RNA delivery technologies for cardiometabolic disorders, operating three clinical-stage programs (SRSD107 Phase 2 Europe, SRSD216 and SRSD101 Phase 1) and a preclinical pipeline.
Highlights
Focus Areas
Biotechnology
Pharmaceutical
Therapeutics
Recent Investors
Financials
$50M
Total Raised
1
Funding round
4
Investors